Log in with your email address username.

×

Important notice

doctorportal Learning is on the move as we will be launching a new website very shortly. If you would like to sign up to dp Learning now to register for CPD learning or to use our CPD tracker, please email support@doctorportal.com.au so we can assist you. If you are already signed up to doctorportal Learning, your login will work in the new site so you can continue to enrol for learning, complete an online module, or access your CPD tracker report.

To access and/or sign up for other resources such as Jobs Board, Bookshop or InSight+, please go to www.mja.com.au, or click the relevant menu item and you will be redirected.

All other doctorportal services, such as Find A Doctor, are no longer available.

[Comment] Encouraging data from ABSORB IV pave the way to new scaffolds

Despite the expectations for the dawn of the vascular reparative therapy era with coronary bioresorbable vascular scaffolds (BVS), the results of large trials published in the past 3 years raised concerns about the safety and efficacy of these devices. Although most studies reported non-inferiority in device-oriented adverse events for the everolimus-eluting Absorb BVS (currently the only one tested in large clinical trials) as compared with the metallic Xience everolimus-eluting stent (EES), pooled patient-level meta-analyses found BVS to be associated with increased risk of 1-year target vessel myocardial infarction and of 2-year device-oriented adverse events, with high relative risks of device thrombosis in both analyses.

email